Come listen to MedSIR Founders Maria Campos, Dr. Javier Cortés, and Dr. Antonio Llombart speak about the MedSIR concept and how we are currently optimizing clinical research in Oncology.

Don’t miss Dr. José Perez, Breast Cancer Specialist, speaking about the role MedSIR plays in his everyday research.

WELCOME TO MEDSIR!

Here we are dedicated to the design and management of clinical trials involving some of the most important current drugs in Oncology such as osimertinib, pembrolizumab, pertuzumab, T-DM1, olaparib, niraparib, eribulin, palbociclib, fulvestrant, radium-223 and many more and we’d be thrilled to help you transform your idea into a high-level strategic clinical trial by applying our simple method:

First off, you confidentially send us your idea… a few lines, or a short synopsis is all we need.

Then, your idea will be reviewed by our network of cancer experts while our statistician develops a realistic scenario for the study to be carried out.

Lastly, we confidentially present the proposal to a potential funder, negotiating a win-win situation that satisfies all parties.

If the project is approved, you will join our team and play a lead role in all study aspects all the way through to the publication of study results. Meanwhile, our clinical operations team professionally manages the trial, respecting ISO 9001-certified quality, while placing a major focus on accrual timelines: The faster we move, the quicker we can produce results and improve patient lives.


We want to announce a substudy proposal!

About 14,69% of patients screened for PHERGain study had failed to enter because of non-measurable disease by Positron Emission Tomography (PET) criteria (PERCIST). Early PET-SCAN evaluation has shown...
READ MORE...
Another big step in PHERGAIN Study

We are glad to announce that PHERGain study “Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy...
READ MORE...
MedSIR will be at 41st Annual San Antonio Breast Cancer Symposium (SABCS)

MedSIR will be attending this 41st Annual event from December 04 - 08, 2018 at Henry B. Gonzalez Convention Center, San Antonio, Texas, USA. We are very excited to be part of...
READ MORE...
100% Recruitment Achieved of EXCAAPE Study!

We are pleased to announce that EXCAAPE study "A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression...
READ MORE...
MedSIR INSIDE OUT – Duna Zaragoza

Today we are happy to spend a brief moment with Duna Zaragoza, Head of Human Resources at MedSIR…we all known her as People Manager. MedSIR Newsletter Team (MS): Thanks Duna, for spending...
READ MORE...
Post ESMO 2018

October 19th was the first day of the annual meeting of the European Society of Molecular Oncology. Nearly 20,000 oncology stakeholders from over 130 countries worldwide attended the conference in Munich, Germany, and the MedSIR team was...
READ MORE...